Keyphrases
Adverse Event Rates
33%
Allogeneic
33%
Carbohydrate Antigen 19-9 (CA19-9)
33%
CD68
33%
CD8+ T Cells
33%
Confidence Interval
100%
Cyclophosphamide
100%
Immune-related Response Criteria
33%
In(III)
33%
Listeria
100%
Live Attenuated
33%
Long-term Survivors
33%
Measurable Disease
33%
Median Overall Survival
33%
Mesothelin
100%
Metastatic Disease
33%
Metastatic Pancreatic Cancer
33%
Microenvironment
33%
Myeloid Cells
33%
Nivolumab
100%
Objective Response
66%
Overall Survival
100%
Pancreas
100%
Pancreatic Adenocarcinoma
33%
Pancreatic Cancer
100%
Pancreatic Tumor Cells
33%
Previously Treated
33%
Progression-free Survival
33%
Response Evaluation Criteria in Solid Tumors (RECIST)
33%
Tumor Microenvironment
33%
Tumor Response
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
25%
CD8 Antigen
25%
Chlordane
25%
Cyclophosphamide
100%
Disease
25%
Listeria
100%
Mesothelin
100%
Metastasis
25%
Neoplasm
25%
Nivolumab
100%
Overall Survival
100%
Pancreas Adenocarcinoma
25%
Pancreas Cancer
100%
Pancreas Tumor
25%
Progression Free Survival
25%
Tumor Microenvironment
25%
Medicine and Dentistry
Adverse Event
7%
Arm
100%
CA19-9
7%
Chlordane
7%
Cyclophosphamide
100%
Cytotoxic T-Cell
7%
Disease
7%
Listeria
100%
Mesothelin
100%
Metastatic Carcinoma
7%
Myeloid Cell
7%
Neoplasm
7%
Nivolumab
100%
Overall Survival
28%
Pancreas Adenocarcinoma
7%
Pancreas Cancer
100%
Pancreas Tumor
7%
Progression Free Survival
7%
Tumor Cell
7%
Tumor Microenvironment
7%
Immunology and Microbiology
Arm
100%
CD68
7%
Cyclophosphamide
100%
Cytotoxic T-Cell
7%
Listeria
100%
Mesothelin
100%
Myeloid
7%
Nivolumab
100%
Overall Survival
28%
Pancreas
100%
Progression Free Survival
7%
Tumor Cell
7%
Vaccine Efficacy
7%
Agricultural and Biological Sciences
CA19-9
33%
Confidence Interval
100%
Cyclophosphamide
100%
Endpoints
33%
Listeria
100%
Mesothelin
100%
Myeloid
33%
Pancreas
100%
T Cell
33%